You Position: Home > Paper
Decision-making of treatment and relative problems about recurrent and drug-resistant gynecologic neoplasms
( views:296, downloads:92 )
- Author:
- No author available
- Journal Title:
- CHINESE JOURNAL OF OBSTETRICS AND GYNECOLOGY
- Issue:
- 11
- DOI:
- 10.3760/cma.j.issn.0529-567x.2010.11.001
- Key Word:
- No keyword available
Abstract： @@ 复发与耐药是恶性肿瘤临床进程中的一个特殊阶段,大多数复发与耐药患者预后不良,甚至不可治愈.妇科恶性肿瘤是常见的实体肿瘤,复发与耐药并不少见,但迄今还存在诸多问题,如定义不统一、个体差异较大、治疗方案存有争议等,治疗决策常常极为棘手.随着治疗理念的革新和治疗手段的进展,相信复发与耐药性妇科恶性肿瘤的预后将会有显著的改观.
- [1]向阳,孙建衡.难治性妇科恶性肿瘤的处理策略[J].2008,(10).
- [2]李小平,崔恒,周敬伟,等.IAP方案治疗复发及耐药性卵巢上皮性癌的临床分析[J].2008,(10).
- [3]Qian W,Lamont A,Jayson G,etc.Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.[J].2003,361(9375).
- [4]Kesic V.Management of cervical cancer.[J].2006,32(8).
- [5]Burger RA,Greer BE,Sorosky JI,etc.Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.[J].2007,25(33).
- [6]Lenhard SM,Kirschenhofer A,Linke R,etc.Predictive value of PET-CT imaging versus AGO-scoring in patients planned for cytoreductive surgery in recurrent ovarian cancer.[J].2008,140(2).
- [7]Bristow RE,Chi DS,Puri I.Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis.[J].2009,112(1).
- [8]Harnett P,Awada A,Piccart-Gebhart MJ,etc.New therapies for ovarian cancer: Cytotoxics and molecularly targeted agents.[J].2008,67(2).
- [9]Harter P,du Bois A.The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence.[J].2005,17(5).
- [10]Vergote I,Jackisch C,Wagner U,etc.Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.[J].2006,24(29).
- [11]Mackey H,Douglas J,McGuire W,etc.Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.[J].2007,25(33).